Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiopronin
Drug ID BADD_D02223
Description Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body. It has been investigated for use in the treatment of arthritis and as a neuroprotective agent in aneurysmal subarachnoid hemorrhage.
Indications and Usage Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.
Marketing Status approved; investigational
ATC Code G04BX16
DrugBank ID DB06823
KEGG ID D01430
MeSH ID D008625
PubChem ID 5483
TTD Drug ID D0A8CJ
NDC Product Code 0093-7909; 69766-033; 43235-0008; 43744-574; 0178-0900; 69575-4037; 58159-057; 0178-0901; 0178-0902; 75877-0004
UNII C5W04GO61S
Synonyms Tiopronin | 2-Thiolpropionamidoacetic Acid | 2 Thiolpropionamidoacetic Acid | Acid, 2-Thiolpropionamidoacetic | alpha-Mercaptopropionylglycine | alpha Mercaptopropionylglycine | Tiopronine | 2-Thiol-propionamido-acetic Acid | 2 Thiol propionamido acetic Acid | Acid, 2-Thiol-propionamido-acetic | Thiopronine | 2-Mercaptopropionylglycine | 2 Mercaptopropionylglycine | Mercaptopropionylglycine | Acadione | Thiola | Captimer | Meprin
Chemical Information
Molecular Formula C5H9NO3S
CAS Registry Number 1953-02-2
SMILES CC(C(=O)NCC(=O)O)S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Leukopenia01.02.02.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.0030.000411%
Mouth ulceration07.05.06.004--Not Available
Myalgia15.05.02.001--
Myasthenic syndrome17.05.04.004; 16.32.01.002; 15.05.08.003; 10.04.05.005--Not Available
Nausea07.01.07.0010.001233%
Nephrolithiasis20.04.01.0020.000411%
Nephropathy20.05.03.001--Not Available
Nephrotic syndrome20.05.01.0020.000616%
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Proteinuria20.02.01.0110.000616%
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.000471%
Rash23.03.13.0010.001849%Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005--Not Available
Respiratory distress22.02.01.012--Not Available
Skin disorder23.03.03.007--Not Available
Skin papilloma23.10.01.002; 16.26.01.002; 11.05.07.001--
Skin wrinkling23.01.03.001--Not Available
Stomatitis07.05.06.005--
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.006--Not Available
Thrombocytopenia01.08.01.0020.000616%Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene